Reclassification Watch

Focused page for evidence freshness, stale evidence, and reclassification-risk monitoring using the existing Review Intelligence and Evidence OS layers.

Safety boundary: synthetic/de-identified only, no PHI, no raw patient identifiers, no final diagnosis, no final ACMG, no treatment recommendation, no clinical release, and qualified human review is required.

Next step

Use this route to inspect de-identified evidence/research context, then request a controlled pilot if the workflow fits. This page is a wrapper over existing Tynixa capabilities, not a new autonomous clinical decision system.